Home2019-08-14T17:27:48+00:00
Loading...
Loading...

Spotlight

Twitter feed

Don't miss the upcoming #AACRdisp19 session, Border Health: Challenges and Opportunities for Control of Cancer Disparities. Talks will highlight cancer disparities facing Latina women, colorectal cancer mortality along the border, and much more. https://t.co/qacgplmDfm

Dana-Farber Cancer Institute receives $5 million gift to create the Edward P. Evans Center for Myelodysplastic Syndromes to help reduce the global burden of #MDS: https://t.co/dqKi0auLmi

Celebrate National Postdoc Appreciation Week (#NPAW2019) by attending the AACR Cancer Careers Clinic TODAY @DrexelUniv from 10AM-1PM! Learn more at https://t.co/XGPq3qxsz4 #AACRpostdoc

New study in @JCO_ASCO from @DrMatulonis shows the PARP inhibitor Niraparib when used as maintenance therapy for women with recurrent #ovariancancer can significantly prolong the time without symptoms or toxicity: https://t.co/lHsF9e00hx

Don’t miss the #AACRdisp19 Opening Session featuring Dr. Lisa C. Richardson of the CDC, as we kick off the AACR Conference on The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Sept. 20 in San Francisco https://t.co/MqVEtnUgUf

AACR Annual Meeting 2020 Call for Abstracts! The abstract submitter will open Tuesday, Sept. 24. Be sure to submit your abstract by Thursday, Dec. 5, 2019. https://t.co/KT0a4NplA7 #aacr2020

Support clinical and postdoc fellows during #NPAW2019 with the hashtag #AACRpostdoc for a chance to have your message featured by AACR Sept. 16-20.

Attention members: Advance Housing Access for #AACR20 starts Sept. 24 at 9 a.m. EST - Sept. 30 at 11:59 p.m. EST. Visit https://t.co/BSAF16gtDu for more information.

The Financial and Physical Toxicity of Immune Checkpoint Inhibitors in Cancer: #ASCOdailynews #financialtoxicity #ImmunoOnc

The Financial and Physical Toxicity of Immune Checkpoint Inhibitors in Cancer

bit.ly

Recent publications

Phase I study of rapid alternation of sunitinib and regorafenib for the treatment of tyrosine-kinase inhibitor refractory gastrointestinal stromal tumors. Clin. Cancer Res.

Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia.

All publications

Announcements

Dr. Jänne, Director Belfer Center for Applied Cancer Science, presents phase I data for HER3 targeting ADC in patients with EGFR mutant lung cancer patients   at the 2019 ASCO Annual Meeting

Research

Target identification and validation image
Target identification and validation
Photo of scientist carefully adding fluid to multiple test tubes
Drug discovery and development
Photo of Belfer Center researcher working at computer
Clinical science and correlatives

Strategic alliances

Graphic showing circular relationship of research, medicine, and industry

Our strategic alliances drive research innovations and lead to improved therapies to benefit cancer patients

Collaborate with us

Our people

Background image is a collage of photos showing Belfer Center members
Background image is a collage of photos showing Belfer Center members

Donor highlight

Robert and Renée Belfer’s transformative cumulative Dana-Farber investment of more than $25 million launched the Robert A. and Renée E. Belfer Center for Applied Cancer Science. Their generosity enabled the Belfer Center to integrate its scientific teams, produce innovative cancer models, partner with industry leaders, and accelerate the development of revolutionary therapies to treat cancer. We are grateful for their vision and incredible support.

Photo of donors, Mr. and Mrs Belfer